---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000004"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:29:32.555327+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions wins $235.8M DoD contract for BioThrax anthrax vaccine

## Summary
- IDIQ contract with U.S. DoD and JPEO-CBRND valued up to $235.8M to supply BioThrax for military PrEP.
- Contract includes 5-year base ending Sep 30, 2028, plus a 5-year option extending to Sep 30, 2033.
- Guaranteed minimum purchase of $20.1M in first year; estimated at least $20M per year thereafter.
- Paul Williams, senior VP products head, notes contract reinforces Emergent's medical countermeasures portfolio.

## SEC filing metadata
- accession: 0001367644-24-000004
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000004/0001367644-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000004/ebs-20240109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000004
- JSON: https://secwatch.observer/filing/0001367644-24-000004.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.